HOME >> BIOLOGY >> NEWS
Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting

Snowmass, Co. (September 9, 2004) Inflammatory Bowel Diseases, comprised of Crohn's Disease and ulcerative colitis, are for the most part incurable and their causes are still unknown. About 1 million Americans suffer from IBD and research around the world on new therapeutic strategies against IBD is being reported at a conference sponsored by the American Physiological Society.

Below are reports on three presentations.

  • Anti-adhesion therapy in the treatment of IBD Julian Panes and Josep M. Pique of the Gastroenterology Department of the Hospital Clinic Barcelona, Spain, note that the localization for leukocytes to inflammatory areas has key implications in the pathogenesis, diagnosis and treatment of IBD. A major effort has been directed toward identifying and characterizing the adhesion glycoproteins that enable leukocytes to bind to vascular endothelial cells. Drugs that specifically target adhesion molecules involved in leukocyte recruitment are effective in treating intestinal inflammation.

    They said that experimental models have shown that blockade of VLA-4, VCAM-1 and P-selectin afford significant amelioration of intestinal inflammation. In experimental models, response to adhesion molecule blockage varies according to the type of inflammatory intestinal condition. In humans VLA-4 immunoneutralization has been effective in inducing remission in Crohn's Disease, but no data is available for ulcerative colitis.

    The researchers call for experimental and clinical controlled trials comparing the effectiveness of different strategies of CAM blockade, and suggest that this therapeutic approach be compared with current therapies.

  • Platelet recruitment in intestinal inflammation modulated by ICAM-1, P-selectin, PSGL-1

    Researchers from LSU and the University of Muenster studied the mechanisms responsible for platelet-WBC and platelet-endothelial cell (EC) interactions that occur in exper
    '"/>



  • Contact: Mayer Resnick
    mresnick@the-aps.org
    301-634-7209
    American Physiological Society
    9-Sep-2004


    Page: 1 2 3

    Related biology news :

    1. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
    2. Novel approaches to current cellular therapies continue progress toward disease prevention
    3. Novel therapies show promise against myeloid leukemia
    4. Novel sensors help clear the air
    5. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
    6. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
    7. Novel therapeutic target identified in fight against Rheumatoid Arthritis
    8. Novel bacterium detoxifies chlorinated pollutants
    9. Novel flu vaccine shows promise in mice
    10. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician
    11. Novel method identifies hidden genes

    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, a registered ... common and aggressive adult brain cancer—announced today the appointments of its first Senior ... with supporting the organization’s initiatives and overall vision. , "Senior Fellows are more ...
    (Date:6/23/2020)... ... June 23, 2020 , ... ... development services, today announced that the company has received ISO9001:2015 certification for ... diagnostics, and research industries. The decision to pursue ISO9001 accreditation demonstrates Kemp’s ...
    (Date:6/23/2020)... (PRWEB) , ... June 23, 2020 , ... In its ... feature interview with Dr. James L. Sherley, M.D., Ph.D., founder and director of ... the company announced on June 16 that starting July 5 it would ...
    Breaking Biology News(10 mins):
    (Date:6/23/2020)... ... June 23, 2020 , ... ... today announced that it has filed an Investigational New Drug application (IND) with ... trial of its lead drug candidate NBTX-001 in patients with panic disorder (PD). ...
    (Date:6/11/2020)... ... June 09, 2020 , ... TRX Systems, developer ... Micro-Tracer Solution, a highly accurate, contact tracing solution for identification of employees ... tracing, a core disease control measure, is a key strategy for preventing further ...
    (Date:5/30/2020)... (PRWEB) , ... May 29, 2020 , ... ... biotech, medical device, diagnostics, and animal health markets, has enabled Cytovale, Inc., a ... cell mechanics and machine learning, to achieve their first patient in (FPI) in ...
    (Date:5/26/2020)... ... 2020 , ... Brilliant , the leading smart home control and lighting ... announce a new integration to bring more convenience, simplicity, and security to the smart ... Connect® can now be controlled from Brilliant’s in-wall touchscreen control panels and mobile app. ...
    Breaking Biology Technology:
    Cached News: